Liver Fibrosis Treatment Market is Estimated to Witness High Growth Owing to Increasing Prevalence of Chronic Liver Diseases | Coherent Maket Insights

The Liver Fibrosis Treatment Market is estimated for 2023 for the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Liver fibrosis is a pathological condition characterized by excessive accumulation of extracellular matrix proteins in the liver. It is caused due to chronic liver injuries from conditions such as hepatitis, alcoholic liver disease and nonalcoholic steatohepatitis. If left untreated, it can further progress to cirrhosis or liver cancer. Currently available treatment options include antivirals, corticosteroids and immunosuppressants.

Get Sample Report of Liver Fibrosis Treatment Market - https://www.coherentmarketinsights.com/insight/request-sample/2320

Market Dynamics:

The liver fibrosis treatment market is expected to witness significant growth owing to increasing prevalence of chronic liver diseases such as hepatitis B and C, non-alcoholic fatty liver disease and alcoholic liver disease across the globe. As per the estimates by WHO, 257 million people were living with hepatitis B infection in 2019. Additionally, chronic excessive alcohol consumption is one of the major factors fueling the disease burden. Furthermore, rising research and development activities focused on developing novel anti-fibrotic drugs is also contributing to the market growth. Some of the key pipeline drugs in late stages of development target processes such as hepatic stellate cell activation and epithelial-to-mesenchymal transition, which play a major role in liver fibrosis pathogenesis.

Rising Prevalence of Chronic Liver Diseases

Chronic liver diseases such as Nonalcoholic fatty liver disease (NAFLD) and Non-alcoholic steatohepatitis (NASH) are becoming highly prevalent worldwide. According to a study, as many as 1 billion people globally are suffering from NAFLD. Increasing consumption of junk and fast food, lack of physical activity are key contributors to the rise of these diseases. This is leading to an increase in liver fibrosis cases. As per estimates, prevalence of NAFLD is projected to rise further in the coming years. With no approved pharmacological treatments available as of now, the treatment relies on managing the progression of fibrosis. This growing patient pool suffering from chronic liver conditions is a major growth driver for the liver fibrosis treatment market.

Increasing Consumption of Alcohol Worldwide

Excessive and chronic alcohol consumption is one of the leading causes of liver diseases. It is estimated that approximately 2 billion people worldwide regularly consume alcoholic beverages. Rising incomes and evolving lifestyles have led to a surge in alcohol consumption globally over the past few decades. Countries like China and India have seen a rapid rise in alcohol intake. This higher alcohol consumption has significantly contributed to the burden of chronic liver diseases like cirrhosis and fatty liver disease. As the complications of alcohol-related liver damage often lead to fibrosis, the growing alcohol consumption trends worldwide present a sizable patient population demanding anti-fibrotic therapies. This is positively impacting the growth of the liver fibrosis treatment market.

Lack of Approved Drug Therapies

Currently, there are no approved pharmacological therapies for directly treating or reversing the process of liver fibrosis. The existing treatment landscape mainly relies on managing the underlying cause and slowing disease progression through lifestyle modifications and off-label use of existing drugs. This lack of approved and effective antifibrotic drug options represents a major challenge for patients and physicians alike. The need for safe and effective anti-scarring therapies provides a massive opportunity for pharmaceutical companies and clinical stage biotechs developing antifibrotic candidates. Successful approval and commercialization of new class of drugs like small molecule anti-fibrotic drugs and gene therapies will be a breakthrough for this market.

Growing Public Awareness about Liver Health

In recent years, there is increasing global awareness about risks of lifestyle-induced chronic conditions like diabetes, obesity and liver diseases. Various non-profit organizations and public health campaigns are actively promoting messages around healthy dietary habits and risks of excessive alcohol intake. This is positively impacting people's knowledge about liver function and factors contributing to various liver disorders. Early diagnosis is critical for effective management of conditions like NAFLD/NASH to prevent advanced liver damage. With greater public understanding, more at-risk individuals are getting screened through regular health checkups. This growing focus on liver health presents commercial opportunities for diagnostic test makers and drives demand for fibrosis assessment and monitoring tools in the long run.

Buy Now to Get 25% Discount on Liver Fibrosis Treatment Market - https://www.coherentmarketinsights.com/insight/buy-now/2320

Rising Research Investments in Novel Treatment Modalities

Significant research efforts are underway to develop safe and effective anti-fibrotic therapies. There is an increased focus on understanding fibrosis pathogenesis at molecular level to identify novel drug targets. Several biotechs and big pharma players have demonstrated promising preclinical data with drug candidates inhibiting key pro-fibrotic pathways and gene expression mechanisms linked to ECM deposition. Currently, over 50 compounds targeting fibrotic markers like TGF-β, CCN2, integrins are under clinical trials. In addition, cell and gene-based therapies are also under investigation for treating end-stage fibrosis and cirrhosis. With substantial funding pouring in, innovations in antifibrotic drug development are expected to revolutionize the liver fibrosis treatment landscape in the coming decade.

If you have any questions or would like to learn more, please feel free to Contact Mr. Shah using the following details:

US: +12067016702

UK: +4402081234027

Coherent Market Insights Pvt Ltd 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States

Email: sales@coherentmarketinsights.com

Choose Coherent Market Insights for unparalleled market analysis and strategic decision-making.

Why Choose Coherent Market Insights?

At Coherent Market Insights, we offer comprehensive market research reports that provide reliable data, analysis, and insights about the Liver Fibrosis Treatment market. Our reports enable strategic decision-making, enhance market understanding, provide competitive intelligence, offer customer insights, mitigate risks, and support investment and funding decisions. With our unbiased analyses conducted by industry experts, we ensure validation, credibility, and long-term business planning.

This release was published on openPR.